Ribosomal protein L23a pseudogene 93 (RPL23AP93)

Ribosomal protein L23a pseudogene 93 (RPL23AP93) is a processed pseudogene of the ribosomal protein L23a (RPL23A) gene. It is non-coding and functions primarily at the RNA level, if at all. RPL23AP93 is not translated into a functional protein and does not encode a structural or catalytic component involved in cellular pathways. Recent studies suggest that the expression level of this pseudogene in melanoma tissues is associated with overall survival, with higher levels marking a potentially better prognosis, possibly through subtle, indirect regulation of immune cell infiltration and other gene networks. However, mechanistic understanding is lacking, and it is not considered a direct therapeutic target. RPL23AP93 has no established aliases or recognized roles beyond biomarker association research in select cancers, and there are no drugs that act on or through this pseudogene. RPL23AP93 belongs to a large family of ribosomal pseudogenes derived from RPL23A, of which there are nearly 100 in the human genome. Pseudogenes like RPL23AP93 may act as non-coding RNAs influencing gene expression, sometimes described as molecular sponges for microRNAs, but their precise biological importance is still under investigation. RPL23AP93's potential as a prognostic biomarker in melanoma has been observed (higher levels in some studies associate with better survival and immune profile), but it is not causally implicated in disease pathways and is not targeted therapeutically.